Angina in  hypertensive patients. With particular reference to the negative chronotropic effects of sympatholytic therapy.
There was no significant difference in the blood pressure and heart rate response of hypertensive patients with and without angina to standardised exercise on a treadmill before and after anti-hypertensive treatment. There was no improvement in exercise tolerance in the hypertensive patients with angina treated with bethanidine, debrisoquine or guanethidine despite a reduction of resting and exercise heart rates after treatment. The negative chronotropic effect of these sympatholytic drugs was less than that of oxprenolol or propranolol, but the hypotensive response was greater. Both of these beta-receptor blocking drug produced an an improvement in exercise tolerance in patients with angina either alone or in combination with other hypotensive therapy. The best control of blood pressure and angina was often achieved by a combination of a sympatholytic drug and beta-receptor blocking drug. In hypertensive patients treated for several years, angina at presentation was occassionally reduced by reduction of blood pressure. Later onset of angina appeared to be unrelated to control of hypertension but to be due to coincidental coronary occlusion. There was no evidence that myocardial infarction was precipitated by postural or exercise hypotension although these effects occasionally precipitated angina.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy / Q000209:etiology*; D001627:Bethanidine / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D003647:Debrisoquin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006145:Guanethidine / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D010096:Oxprenolol / Q000627:therapeutic use; D005082:Physical Exertion; D011433:Propranolol / Q000627:therapeutic use; D013565:Sympatholytics / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D013565:Sympatholytics; D010096:Oxprenolol; D008750:Methyldopa; D011433:Propranolol; D001627:Bethanidine; D003647:Debrisoquin; D006145:Guanethidine